Sino Biopharm Southern Headquarters settles in Huangpu

Sino Biopharmaceutical Limited's Southern Headquarters has established its presence in Guangzhou International Biological Island in Huangpu district, marking a significant move in response to the nation's strategy in terms of the Greater Bay Area. 

The strategy aims to import leading global drug pipelines, drive domestic clinical transformation and industrialization. The headquarters has already introduced several overseas clinical projects, including treatments for non-alcoholic fatty liver disease and cutting-edge cancer immunotherapy.

Looking ahead, Sino Biopharm plans to operate with dual cores, utilizing the Southern Headquarters and its overseas subsidiary, invoX. This plan involves importing global drug pipelines through acquisitions while facilitating clinical transformation and industrialization in Huangpu district, forming a dual circulation system both domestically and internationally.

The move has been highly valued by the People's Government of Guangzhou Municipality as it recognizes the headquarters' potential to accelerate innovation in drug development and elevate the international competitiveness of the local pharmaceutical industry. 

With the Southern Headquarters now established, Huangpu's bio-pharmaceutical sector anticipates further growth, attracting more leading enterprises and high-quality projects to contribute to the establishment of a global hub for biomedical innovation and industry development.

Share - WeChat